RPEL proteins, which contain the G-actin-binding RPEL motif, coordinate cytoskeletal processes with actin dynamics. We show that the ArhGAP12-and ArhGAP32-family GTPase-activating proteins (GAPs) are RPEL proteins. We determine the structure of the ArhGAP12/G-actin complex, and show that G-actin contacts the RPEL motif and GAP domain sequences. G-actin inhibits ArhGAP12 GAP activity, and this requires the G-actin contacts identified in the structure. In B16 melanoma cells, ArhGAP12 suppresses basal Rac and Cdc42 activity, F-actin assembly, invadopodia formation and experimental metastasis. In this setting, ArhGAP12 mutants defective for G-actin binding exhibit more effective downregulation of Rac GTP loading following HGF stimulation and enhanced inhibition of Rac-dependent processes, including invadopodia formation. Potentiation or disruption of the G-actin/ArhGAP12 interaction, by treatment with the actin-binding drugs latrunculin B or cytochalasin D, has corresponding effects on Rac GTP loading. The interaction of G-actin with RPEL-family rhoGAPs thus provides a negative feedback loop that couples Rac activity to actin dynamics.
S
patial and temporal control of the actin cytoskeleton in response to local signalling or mechanical cues plays a critical role in development and disease [1] [2] [3] . Underpinning it is the regulation of actin treadmilling, the dynamic transition between the monomeric (G-actin) and polymerized (F-actin) forms of actin 1, 4 , which is controlled by small GTPases of the rho family 5, 6 . Rho GTPase activity is potentiated by multiple rho GEF proteins, which catalyse GTP loading and effector protein binding 7, 8 , and antagonized by inhibitory rho GTPase-activating proteins (rho GAPs), which catalyse GTP hydrolysis 9, 10 . Both are regulated by specific subcellular targeting, and by biological and mechanical signals, but relatively little is known about how their activity responds to the status of the actin cytoskeleton.
One connection between the cytoskeletal dynamics and control of protein function is provided by the RPEL proteins, which act as G-actin sensors 11, 12 . Their regulatory domains contain RPEL motifs (Pfam PF02755), short polypeptide sequences that bind G-actin 13 . Two RPEL protein families, the MRTFs and the Phactrs, have been characterized 11, 12, 14, 15 . The MRTFs are coactivators for the SRF transcription factor, regulating the expression of dozens of structural and regulatory cytoskeletal proteins 11, 16, 17 , whereas the Phactrs regulate cytoskeletal dynamics by mechanisms that are poorly understood 14, 15, 18, 19 . G-actin controls the subcellular localization and activity of the MRTFs and Phactrs, at least in part by binding competitively with their regulatory and effector proteins, such as importin αβ and PP1, to sites within their regulatory RPEL domains 14, 15, 20, 21 . Here we characterize two hitherto unidentified RPEL protein families, the ArhGAP12 and ArhGAP32 subfamilies of Rac1/ Cdc42-specific rho GAPs [22] [23] [24] [25] . The ArhGAP12 family is associated with actin-dependent cell-surface structures and processes, including adherens junctions 23, [26] [27] [28] , plasma membrane blebs 29 , phagocytosis 30 and dendritic spines 31 , whereas the proteins of the ArhGAP32 family have been implicated in protein trafficking and neuronal development 25, 32 . However, little is known about their regulation.
We show that binding of G-actin to an atypical RPEL motif adjoining the ArhGAP12 GAP domain inhibits its GAP activity for Rac1 in vitro. Disruption of the G-actin/ArhGAP12 interaction potentiates GAP activity in vivo. Our findings demonstrate that G-actin/ ArhGAP12 interaction constitutes a feedback loop that couples Rac/Cdc42 GTP loading to the state of cytoskeletal dynamics.
Results
Two subfamilies of ArhGAP proteins contain a G-actin-binding motif. The starlet sea anemone Nematostella vectensis A7RG60 protein contains a single canonical RPEL motif between its PH and GAP domains (http://pfam.xfam.org/family/rpel; Supplementary  Fig. 1a,b) . The A7RG60 RPEL-GAP region is closely related to two subfamilies of vertebrate ArhGAP proteins, ArhGAP9, 12, 15, 27 and ArhGAP32, 33, although the RPEL motif in these proteins lacks the conserved RPEL glutamate residue (Fig. 1a,b and Supplementary Fig. 1c,d ). This residue does not directly contact the bound actin, however, but contacts a second G-actin/RPEL unit in proteins containing multiple RPEL motifs 33 .
To test whether the ArhGAP non-consensus RPEL motif indeed binds G-actin, we performed fluorescence anisotropy assays 34 ( Fig. 1b,c) . Peptides encompassing the A7RG60-, ArhGAP12-and ArhGAP32-family RPEL motifs bound G-actin with micromolar affinities, comparable to those of the MRTFs and Phactrs 13, 14, 34 , and binding was impaired to varying extents by an alanine substitution of the core RPEL arginine ( Fig. 1c and Supplementary Fig.  1e ). Biolayer interferometry analysis of a glutathione S-transferase (GST)-RPEL ArhGAP12 fusion protein gave a comparable result (2.85 μM; Supplementary Fig. 1f) .
Intact ArhGAP12 binds G-actin.
In MDCK epithelial cells, where ArhGAP12 promotes cell scattering 23 , actin was readily detectable in ArhGAP12 immunoprecipitates and its recovery decreased following serum stimulation, as seen with other RPEL proteins ( Fig. 2a ) 11, 14 . Similarly, ArhGAP12 co-immunoprecipitated with RPEL-family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability the non-polymerizable actin derivative R62D 35 following transient expression in NIH3T3 cells (Fig. 2b) . ArhGAP12 did not co-localise with the F-actin cytoskeleton in either cell type ( Supplementary   Fig. 1g ). Actin binding was not affected by the deletion of the SH3, WW or PH domains but was substantially reduced by the mutation or deletion of the RPEL motif (Fig. 2b) . Immobilized recombinant GST-ArhGAP12 and GST-ArhGAP32 derivatives could recover purified rabbit skeletal muscle LatB-actin from solution, provided the RPEL motif was intact ( Fig. 2c and Supplementary  Fig. 1h ). Size-exclusion chromatography of complexes formed between LatB-actin and ArhGAP12 ΔN resolved an apparent 1:1 complex of a M r of 90 kDa, whose formation was abolished by the R582A RPEL mutation (Fig. 2d) ; in contrast, ArhGAP1, which does not contain an RPEL motif, did not bind actin in this assay ( Supplementary Fig. 1i ).
ArhGAP12/G-actin interaction involves both the RPEL motif and sequences within the GAP domain. Using biolayer interferometry, we determined the affinity of LatB-actin for ArhGAP12 ΔNΔP to be 40.3 ± 1.5 nM (Fig. 3a) . This is substantially greater than the approximately micromolar affinity of the G-actin/RPEL motif-peptide interaction and suggests that G-actin might contact additional sequences in the RPEL-GAP domain. To investigate the interaction between G-actin and ArhGAP12 in detail, we determined the structure of ArhGAP12 ΔNΔP bound to LatB-actin (hereafter ArhGAP12/G-actin) at a resolution of 2.6 Å ( Fig. 3b and Table 1 ). The asymmetric unit contains four virtually identical copies of the complex, which superimpose with root-meansquare deviations (RMSDs) ranging from 0.18 Å to 0.35 Å (over 500 Cα atoms; Supplementary Fig. 2a ). ArhGAP12 forms a striking U-shape in the ArhGAP12/G-actin complex, clasping G-actin with its RPEL motif and GAP domain, which wrap around subdomains 1 and 3 (Fig. 3b) . The extended ArhGAP12/G-actin interaction surface (1,700 Å 2 ) includes close contacts between the RPEL motif and the G-actin hydrophobic cleft and ledge ( Fig. 3c and Supplementary  Fig. 2b) , and between the GAP domain and a hydrophobic niche at the subdomain 1/3 interface, composed of actin I75, I175 and R177, and P109, L110 and P112 from the actin Pro-rich loop ( Fig. 3d and Supplementary Fig. 2c ).
The ArhGAP12 RPEL motif interacts in a manner largely indistinguishable from that seen in canonical RPEL motif/G-actin complexes 13, 33, 36 but makes two additional contacts through T571 and F578 in helix α1 ( Fig. 3c and Supplementary Fig. 2d ). An alanine substitution of the conserved RPEL motif core residue R582, or helix α1 hydrophobic residues L575 and L579, greatly reduced the recovery of LatB-actin by ArhGAP12 ΔNΔP in the pulldown assay (Fig. 3e) . Supplementary Fig. 8 .
The GAP domain structure is essentially identical (RMSD 0.58 Å, 164 Cα atoms) to a previously determined structure of the ArhGAP15 GAP domain (PDB 3BYI; Supplementary Fig. 2e ). The aromatic side chain of F650, from its helix α5/α7 unit, is deeply buried in the hydrophobic niche, whereas L642, A643 and M677 interact with the niche edges. These interactions are further stabilised by a network of hydrogen bonds formed between N641, Q646, H654 and E681 from the ArhGAP12 helix α5/α7 unit and actin E72, L110, I175 and K113, respectively ( Fig. 3d and Supplementary Fig. 2c) . Alanine-or charge-substitution of F650 reduced the recovery of Biosensors loaded with GST-ArhGAP12 ΔNΔP were incubated with different concentrations of G-actin, which was washed out at 400 s. The indicated K d is the mean ± s.e.m.; a representative of three independent experiments is shown. b, The ArhGAP12 ΔNΔP/LatB-actin complex. ArhGAP12 ΔNΔP is shown as blue ribbon and LatB-actin in white surface representation, with the subdomains 1 and 3 indicated and the hydrophobic cleft, ledge and niche surfaces coloured in blue, pink and yellow, respectively. The Gap domain catalytic arginine finger is indicated. c, RPEL-actin interactions (top). The RPEL residues interacting with actin are shown as sticks; the RPEL sequence, secondary structures and interacting residues (mutated residues are highlighted in green) are summarized (bottom). d, Gap domain interactions with the actin hydrophobic niche. The ArhGAP12 residues interacting with the actin niche or stabilising the orientation of the helices are shown as sticks. The Gap domain helix interaction residues and secondary structures are summarized as in c, with asterisks indicating the residues implicated in interaction with rho-family GTPases 10 (catalytic arginine finger R637 in red). e, Effect of RPEL motif and GAP domain mutations on G-actin binding, assessed by pulldown assay as in Fig. 2c and detected by staining with Coomassie blue. The LatB-actin recovery, quantified relative to GST-ArhGAP12 ΔNΔP WT, is indicated below the gels. The black and open arrowheads point to ArhGAP12 and actin, respectively. Data are representative of three experiments. f, Summary of Octet biolayer interferometry assays for GST-ArhGAP12 ΔNΔP, its mutant derivatives and GST-RPEL. n, number of independent experiments as indicated; n.d., no binding detectable under the assay conditions. The M r values (kDa) are indicated. See Supplementary Fig. 2 for the related data. The source data for a,f are shown in Supplementary Table 1. Unprocessed Coomassie gels are shown in Supplementary Fig. 8 .
G-actin in the pulldown assay, with or without additional alanine substitutions at Q646 and H654 (Fig. 3e) . Biolayer interferometry analysis demonstrated that mutation of the GAP helix α5/α7 unit reduced binding affinity approximately 9-fold, whereas the RPEL R582A mutation reduced it 1,300-fold; binding of actin to a protein containing both mutations was undetectable ( Fig. 3f and Supplementary Fig. 2f ). Thus, the high binding affinity of G-actin for ArhGAP12 arises from contacts with both the RPEL motif and GAP domain.
G-actin inhibits ArhGAP12 GAP activity in vitro. We next investigated the effect of ArhGAP12/G-actin interaction on GAP activity. In a colorimetric GAP assay measuring phosphate release, ArhGAP12 potentiated GTPase activity of Rac1 and Cdc42, but not RhoA ( Supplementary Fig. 3a-c ), in agreement with previous studies of ArhGAP12-and ArhGAP32-family members [22] [23] [24] [25] ; however, it remains possible that other GTPases of the rho family are ArhGAP12 targets. GAP activity towards Rac1 was unaffected by the presence of ArhGAP12 N-terminal sequences including the RPEL motif, or by RPEL point mutations that reduce G-actin binding (Fig. 4a) , but impaired by the mutation of R637, the catalytic 'arginine finger' (Fig. 4a) . Thus, in the absence of actin, the RPEL motif does not affect the in vitro catalytic activity of ArhGAP12.
Inclusion of increasing concentrations of LatB-actin in the GAP reactions effectively inhibited ArhGAP12 GAP activity in vitro ( Fig. 4b and Supplementary Fig. 3d ). Strikingly, the RPEL mutations R582A and L575A L579A, which reduce the ArhGAP12/G-actin interaction, rendered the GAP activity insensitive to inhibition by LatB-actin (Fig. 4b) , as did mutations F650A and F650D, which weaken the interaction between helix 5 of the GAP domain and the actin hydrophobic niche (Fig. 4c) . Thus, inhibition of ArhGAP12 GAP activity requires contact between actin and both the GAP domain and the RPEL motif.
G-actin partially occludes the GTPase binding site in the complex. To further understand the molecular mechanism by which G-actin binding inhibits ArhGAP12 activity, we modelled the interaction of Rac and Cdc42 with ArhGAP12. Superposition of the structure of the MgcRacGAP/Cdc42 complex GAP domain (PDB ID 5C2J) onto that of the ArhGAP12/G-actin (RMSD = 0.63 Å for 123 Cα atoms) revealed a substantial steric clash-23.7% of GTPase atoms-between G-actin and Cdc42, and superposition of the Rac1 structure (PDB 5N6O) onto this model (RMSD 0.50 Å for 148 Cα atoms) revealed a similar clash for Rac1 (23.5%; Fig. 4d and Supplementary Fig. 3e ). To test this we coexpressed ArhGAP12 derivatives with Rac
G12V
, which is locked in the GTP-bound state, and assessed the ability of a GST-PAK CRIB domain fusion protein to recover ArhGAP12 from cell lysates in association with Rac. Mutations in the RPEL motif and GAP domain that impair the G-actin/ArhGAP12 interaction increased ArhGAP12 recovery in this assay (Fig. 4e) . Together, these data suggest that the GAPdomain interaction with the actin hydrophobic niche constrains its position so as to inhibit interaction with its substrate GTPases.
ArhGAP12 controls GTP loading on Rac and Cdc42 in melanoma cells. ArhGAP15, a member of the ArhGAP12 family, is implicated in the maintenance of basal Rac.GTP levels in various cell types [37] [38] [39] . To investigate the role of ArhGAP12 in the regulation of rho-family GTPases, we studied melanoma cells, whose behaviour in invasiveness and experimental metastasis assays is Rac/ Cdc42 dependent [40] [41] [42] [43] [44] . In B16F10 melanoma cells, short interfering RNA (siRNA)-mediated depletion of ArhGAP12 did not appreciably affect the transcription of other ArhGAP12-and ArhGAP32-family members ( Supplementary Fig. 4a ,b) but increased GTP loading on Rac and Cdc42 (Fig. 5a,b) , as did the depletion of ArhGAP32 ( Supplementary Fig. 4c ). We used the RaichuEV-Rac FRET-based biosensor 45 to test how ArhGAP12 affects the kinetics of GTP loading on Rac. In agreement with the pulldown experiments, the biosensor detected elevated basal GTP loading on Rac in ArhGAP12-depleted cells (Fig. 5c) ; following stimulation by HGF, downregulation was inhibited, taking at least twice as long to decrease to 50% of peak levels (Fig. 5d ,e and Supplementary  Fig. 4d ). Thus, ArhGAP12 antagonizes Rac and Cdc42 activity in B16F10 melanoma cells.
ArhGAP12 controls invadopodia and experimental metastasis in melanoma cells. Invadopodia are actin-rich membrane protrusions that degrade the extracellular matrix to drive the invasion of tumour cells 46 . Depletion of ArhGAP12 potentiated invadopodia formation by B16F10 and B16F2 melanoma cells, their less-invasive parent B16F0, and MDA-MB-231 mammary carcinoma cells ( Fig. 6a and Supplementary Fig. 4e ,f); in B16F10 cells, invadopodia formation was strongly dependent on Rac and to a lesser extent on Cdc42 (Fig. 6b ). ArhGAP12 depletion also significantly increased the ability of B16F10 and B16F0 cells to induce experimental metastasis in the mouse tail-vein assay (Fig. 6c ) without affecting cell proliferation ( Supplementary Fig. 4g,h ). Increased metastasis was strongly dependent on Rac ( Fig. 6d ) and required MRTF-SRF signalling, as expected from our previous studies of B16F2 cells (Fig. 6d ) 47 . Consistent with this, ArhGAP12-depleted B16F10 cells exhibited a Rac-dependent increase in F-actin ( Supplementary  Fig. 5a ,b), which was accompanied by increased nuclear accumulation of MRTF-A and increased expression of MRTF-SRF target genes ( Supplementary Fig. 5c,d ). ArhGAP12 also contributes to the maintenance of basal Rac activity in NIH3T3 fibroblasts, where it is the only family member expressed ( Supplementary  Fig. 5e ). In resting cells, its depletion increased F-actin levels, and promoted MRTF-A nuclear accumulation and expression of MRTF-SRF target genes 11 ( Supplementary Fig. 5f -i). ArhGAP12 thus controls Rac-dependent processes in melanoma and fibroblast cells.
G-actin binding controls ArhGAP12 GAP activity in vivo.
We next investigated the role of G-actin in ArhGAP12 regulation in vivo. B16F10-derived cell lines conditionally expressing siRNAresistant ArhGAP12 derivatives were depleted of endogenous ArhGAP12, and their behaviour compared in the invadopodia and metastasis assays. Re-expression of both wild-type and R582A ArhGAP12 effectively suppressed the increased invadopodia formation, experimental metastasis and F-actin formation associated with ArhGAP12 depletion; the R582A mutant was more effective than c, Alanine or aspartate substitutions at niche-contact residue F650 of ArhGAP12 ΔNΔP do not affect GAP activity but relieve the inhibitory effect of LatB-actin. a-c, GAP activity towards Rac1 was assessed using a colorimetric assay for inorganic phosphate (Pi) release. Data were fitted by nonlinear regression; data represent the mean ± s.e.m.; n = 3 (a, left and b) and 4 (a, right and c) independent experiments. d, Model of Rac1 bound to ArhGAP12. The GAP domain of the MgcRacGAP/Cdc42.GDP structure (PDB ID 5C2J) was superimposed onto the GAP domain of the ArhGAP12 ΔNΔP/actin structure. The Rac1 structure (PDB ID 5N6O) was then superimposed onto the Cdc42 model (RMSD 0.50 Å, 148 Cα atoms). Exposed and occluded Rac1 residues are shown as green and red ribbons, respectively, and GDP in orange. The degree of occlusion is similar for Cdc42 (23.7%) and Rac1 (23.5%). e, FLAG-ArhGAP12 derivatives and constitutively active Myc-Rac G12V were coexpressed in NIH 3T3 cells, and the recovery of ArhGAP12 and Myc-Rac G12V in GST-PAK CRIB-pulldown assays assessed by immunoblotting. Representative immunoblots from three independent experiments are shown. The M r values (kDa) are indicated. See Supplementary Fig. 3 for the related data. The source data for a-c are shown in Supplementary Table 1 .
Unprocessed blots are shown in Supplementary Fig. 8 .
the wild-type protein at suppressing invadopodia formation and was as effective as the wild-type protein in the other assays, although it was expressed at a lower level (Fig. 7a,b and Supplementary Fig. 6a ). We used the depletion-rescue approach in conjunction with the RaichuEV-Rac FRET biosensor to investigate the consequences of the G-actin/ArhGAP12 interaction for Rac GTP loading in vivo. B16F10 melanoma cells transiently expressing siRNA-resistant wild-type or RPEL R582A mutant ArhGAP12 were depleted of endogenous ArhGAP12 and the kinetics of Rac GTP loading following HGF stimulation measured. In this setting, expression of ArhGAP12 R582A lowered the basal level of Rac GTP loading more than wild-type ArhGAP12 and altered the kinetics of Rac GTP loading, such that Rac downregulation occurred more rapidly ( Fig. 7c and Supplementary Fig. 6b ). Consistent with this, Rac.GTP-pulldown assays from B16F10 cells transiently expressing ArhGAP12 derivatives, together with Myc-tagged Rac, showed that Rac.GTP levels were lower in cells expressing the ArhGAP12 mutants R582A and L575A L579A, which cannot bind G-actin, than in cells expressing wild-type ArhGAP12, even though the mutant proteins were expressed less efficiently (Fig. 7d) . Consistent with these results, expression of ArhGAP12 R582A in tetracyclineinducible NIH3T3 cell lines decreased F-actin levels to a greater extent than wild-type ArhGAP12 ( Supplementary Fig. 6c,d) .
The preceding results show that the RPEL motif exerts an inhibitory effect on ArhGAP12 Rac GAP activity in vivo. To verify that this is a direct result of changes in ArhGAP12/G-actin interaction, we examined the effects of actin-binding drugs on ArhGAP12 activity. Cytochalasin D (CD) and latrunculin B (LatB) both bind G-actin, promoting F-actin disassembly, but they have opposing effects on RPEL proteins: CD binds G-actin competitively with the RPEL motif and disrupts G-actin binding, whereas LatB is compatible with the G-actin/RPEL interaction 11, 12 . Accordingly, treatment of B16F10 cells with CD decreased Rac.GTP levels, whereas LatB treatment potentiated it, as assessed using the GST-PAK-pulldown assay (Fig. 7e) . Strikingly, neither drug treatment affected the Rac. GTP levels in ArhGAP12-depleted cells, indicating that their effects require ArhGAP12 (Fig. 7f,g and Supplementary Fig. 6e ). Similar results were obtained following a comparison of wild-type and ArhGAP12-knockout fibroblasts (Fig. 7h) . Thus, G-actin controls cellular Rac GTP loading through its interaction with ArhGAP12-family GAPs.
Discussion
We have shown that the ArhGAP12-and ArhGAP32-family rhoGAPs are RPEL proteins, each containing a single atypical RPEL motif immediately N-terminal to the GAP domain. G-actin forms a 1:1 complex with ArhGAP12, inhibiting its GAP activity towards Rac1 and Cdc42. Actin makes canonical interactions with the RPEL motif and also interacts with the GAP domain through a hydrophobic 'niche' on its subdomain 1/3 interface. Although the GAP domain contacts contribute only modestly to the overall G-actinbinding affinity, they are critical for the repressive effect of actin binding on GAP activity. Inhibition of GAP activity by occlusion of the GTPase binding site is also seen in the inhibitory interaction between DLC1 and the SH3 domain of p120RasGAP 48 . Our results show that binding of G-actin to ArhGAP12 downregulates its GAP activity in melanoma cells in vivo, sculpting the kinetics of Rac.GTP accumulation and controlling Rac-dependent processes, such as invadopodia formation and experimental metastasis. Extracellular chemical or environmental signals and changes in cell differentiation state are all associated with changes in actin dynamics. Given that G-actin diffuses rapidly, ArhGAP12-and ArhGAP32-family members would effectively link the downstream functions of their target GTPases, which include F-actin assembly, to the general state of actin cytoskeletal dynamics, thereby constituting a feedback loop (Fig. 7i, left) . Members of the ArhGAP12 family are also enriched at specific subcellular locations, such as epithelial cell junctions and macrophage phagocytic cups 23, 30 . In such settings they could directly monitor local G-actin fluctuations induced by their target GTPases, thereby fine-tuning GTPase activity, as part of a local homeostatic feedback loop (Fig. 7i, right) . Indeed, it has been proposed that ArhGAP12 fulfils such a function at the phagocytic cup 30 and we are currently investigating this further. The ArhGAP12-and ArhGAP32-family rhoGAPs contain only a single atypical RPEL motif lacking the conserved RPEL core glutamate (Pfam PF02755). Our previous studies of multivalent G-actin/RPEL complexes showed that the glutamate contacts a second RPEL/G-actin unit on its C-terminal side 33, 36 and it is therefore unsurprising that atypical RPEL motif peptides bind G-actin with comparable micromolar-range affinities 13, 14 . We estimated the G-actin-binding affinity of the intact ArhGAP12 RPEL-GAP fragment to be 40.3 ± 1.5 nM, which is comparable to that estimated for the MRTF-A RPEL domain (~25 nM) 35 . We therefore think it likely that the ArhGAPs and MRTFs will be similarly responsive to changes in G-actin concentration, despite that the ArhGAPs contain one rather than three RPEL motifs. The development of sensors that allow tracking of G-actin concentration and measurement of the G-actin/RPEL interaction in vivo will be important to resolve this issue.
The actin hydrophobic niche identified here is conserved among different actin-family members and it is therefore unlikely that different actins have differential effects on ArhGAP12 activity. Although not previously implicated in interactions with other G-actin-binding proteins, the niche region mediates actin-actin interactions within the ADP F-actin filament 49, 50 . However, in this context it displays a more open conformation, with the subdomain Fig. 6d . Representative results of three experiments are shown; n = 5 mice; two-tailed Mann-Whitney tests. c, HGF-induced Rac GTP loading was imaged using the RaichuEV-Rac biosensor. FLAG-ArhGAP12 WT or R582A resistant to siRNA were transiently re-expressed in serum-starved ArhGAP12-depleted B16F10 cells. Images were acquired from control (n = 96), +ArhGAP12 WT (n = 58) and +ArhGAP12 R582A (n = 37) cells. (i) Basal Rac GTP loading, measured by the FRET/CFP ratio over 10 min before stimulation. Data represent the mean ± s.e.m.; two-tailed Mann-Whitney tests. Note the lower expression level of ArhGAP12 R582A. (ii) Kinetics of Rac GTP loading following HGF stimulation, normalized taking the basal activity in control cells as 1.0. Data represent the mean ± s.e.m. d, Immunoblot analysis of GST-PAK Rac-pulldown assays using lysates of B16F10 cells co-transfected with FLAG-ArhGAP12 derivatives and Myc-Rac. Immunoblots are representative of three independent experiments. e, B16F10 cells, maintained in 0.3% FCS, following treatment with cytochalasin D (CD) or LatB for 30 min before Rac.GTP-pulldown assays were performed. Data represent the mean ± s.e.m.; n = 3 independent experiments; two-tailed unpaired t-test. f, Cells transfected with control or ArhGAP12 siRNA were maintained in 10% FCS and treated with cytochalasin D for 30 min before Rac.GTP-pulldown assays were performed. Data represent the mean ± s.e.m.; n = 5 (control) and 11 (siArhGAP12) independent experiments; two-tailed unpaired t-test. g, Cells as in f were treated with LatB for 30 min before Rac.GTP-pulldown assays were performed. Immunoblots are representative of three independent experiments. h, Wild-type and ArhGAP12-knockout (KO) MEFs were treated with LatB (30 min) and PDGF (5 min) before Rac.GTP-pulldown assays were performed. Data are the mean ± s.e.m.; n = 5 (WT) and 3 (KO) independent experiments; two-tailed unpaired t-tests. The M r values (kDa) are indicated. i, Global (left) and local (right) regulation by RPEL rhoGAP proteins. See Supplementary Figs. 5,6 for the related data. The source data for a-c,e,f,h are shown in Supplementary Table 1 . Unprocessed blots are shown in Supplementary Fig. 8 .
1 Pro-rich loop interaction being disrupted to form the phosphate exit channel. ADP-ribosylation of residue R177, at the niche edge, by bacterial toxins disrupts filament formation (reviewed in ref. 51 ). The niche makes intimate contacts with the helix 5-7 unit of the rhoGAP domain, just C-terminal to the catalytic arginine, which is implicated in GTPase recognition 10 . ArhGAP12 F650, which docks in the niche, is conserved or substituted by tyrosine or histidine in the other RPEL GAPs but is generally hydrophilic in other rhoGAPs 10 ( Supplementary Fig. 7 ). This, and the lack of RPEL motifs in other rhoGAPs, suggests that only the ArhGAP12 and ArhGAP32 families are regulated by G-actin.
ArhGAP12 is present at high levels at adherens junctions, where it promotes cell-cell adhesion 23, [26] [27] [28] , and at other actinregulated cell surface structures, such as plasma membrane blebs, phagocytic cups and dendritic spines [29] [30] [31] . Both ArhGAP12 and ArhGAP15 localization is controlled by PI 3-kinase signalling 30, 39 and the PH domain of the ArhGAP12-family member ArhGAP9 binds the phospholipid products of PI 3-kinase 52 . The PH domain is just N-terminal to the RPEL motif, so we are currently investigating whether G-actin binding also affects its function. The two ArhGAP32 family GAPs contain an SH3 domain N-terminal to the RPEL motif and it will be interesting to see if G-actin influences its interactions.
ArhGAP12 suppresses the basal levels of GTP loading on Rac and Cdc42 in mouse melanoma cells. Similarly, the ArhGAP12-family protein ArhGAP15 suppresses Rac GTP loading in diverse settings, including brain, glioma, 293 kidney cells and myeloid lineages [37] [38] [39] . This could occur in two ways. First, depletion of ArhGAP12 from specific subcellular locations might increase Rac.GTP at these locations, which could rapidly exchange with Rac pools elsewhere in the cell. Alternatively, depletion of ubiquitously localized ArhGAP12 might impact the global Rac.GTP level directly, although one might expect such effects would be small given most cells express multiple rho GAPs 9, 10 . Either way, depletion of ArhGAP12 in B16F10 cells raises Rac GTP loading sufficiently to potentiate invadopodia formation and experimental metastasis [40] [41] [42] , the latter appearing to reflect Rac-dependent F-actin assembly and MRTF activation. Interestingly, low expression levels of the ArhGAP12 family are associated with poor survival in human melanoma in the TCGA database analysed using the OncoLnc tool (http://www.oncolnc.org).
We found that the direct G-actin/ArhGAP12 interaction plays a significant role in the control of ArhGAP12 GAP activity. In melanoma cells, ArhGAP12 RPEL mutants defective in actin binding exhibited higher GAP activity, were more effective at Rac downregulation following growth factor stimulation andin at least some biological assays, such as invadopodia formation-were significantly more active than the wild-type protein.
Moreover, the actin-binding drugs cytochalasin D and LatB had opposing effects on Rac GTP loading, consistent with their differential effects on the G-actin/RPEL interaction, which were ArhGAP12 dependent. Interestingly, in macrophages, which exhibit ArhGAP12-dependent phagocytosis, cytochalasin D and actin siRNA inhibit Rac and Cdc42 activation, and lipopolysaccharide-stimulated phagocytosis 30, 53 , while in neutrophils, LatB treatment prevents ArhGAP15-dependent Rac downregulation following PI3K activation 39 . Our findings suggest that these observations reflect the direct control of ArhGAP12-family proteins by G-actin in these contexts.
The RPEL motif present in the ArhGAP12 and ArhGAP32 proteins couples their activity to the surrounding availability of G-actin (Fig. 7i) . We therefore consider it likely that these rhoGAPs will be involved in biological processes that are critically reliant on local control of F-actin assembly. Our future work will focus on elucidating how the activity of the ArhGAP12-family members relates to fluctuations in local G-actin concentration.
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Methods
Plasmids. ArhGAP12 complementary DNA (short isoform encoding a 791-aminoacid protein; UniProt S4R248) was amplified by PCR from an NIH 3T3 cDNA library using standard techniques. ArhGAP12 derivatives were expressed in mammalian cells with an N-terminal FLAG tag in pEF-plink 11 or pcDNA4TO (Invitrogen) or as N-terminal green fluorescent protein (GFP) fusion in pcDNA6.2-N-EmGFP (Invitrogen) and in bacteria as GST fusion in the pGex-6P-2 vector. Point mutants and siRNA-oligonucleotide 11-resistant ArhGAP12 derivatives were generated by site-directed mutagenesis (three mismatches: 5ʹ-GAG CAT GTC-3ʹ to 5ʹ-GAA CAC GTT-3ʹ; Quikchange, Agilent). Deletion mutants were created using the Phusion high-fidelity protocol (New England Biolabs). For lentiviral transduction, FLAG-ArhGAP12 sequences were cloned into a modified pTripz vector (Dharmacon), where RFP and microRNA regulation sequences were replaced by a bGH poly(A) sequence using In-fusion HD cloning (Takara). The ArhGAP32 RPEL-GAP domain (amino acids 339-569) was expressed in bacteria as a GST fusion using the pGex-6P-2 vector. Expression plasmids for actin R62D and Rac have been described 35 . All plasmids were sequenced using Sanger sequencing.
Protein expression, purification and size-exclusion chromatography.
Rabbit skeletal muscle LatB-actin was prepared as described 34 . ArhGAP12 and ArhGAP32 protein expression was induced at 37 °C in Escherichia coli Rosetta (DE3) pLysS. The bacteria were harvested by centrifugation and lysed in 20 mM Tris, pH 6.8 and 8.5 respectively, 150 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride and protease inhibitors (Roche). The GST-fusion proteins were adsorbed onto a glutathionesepharose resin (GE Healthcare) and ArhGAP12 derivatives were recovered by cleavage with 3C protease overnight at 4 °C in 20 mM Tris pH 6.8, 150 mM NaCl, 10 mM MgCl 2 and 1 mM DTT. The proteins were then purified by sizeexclusion chromatography using a Superdex 200 column (GE Healthcare) in 50 mM Tris, pH 6.8, 150 mM NaCl, 10 mM MgCl 2 and 1 mM DTT. The purity of the proteins was examined by SDS-PAGE and Coomassie brilliant blue staining ( Supplementary Fig. 3b ).
Analytical size-exclusion chromatography and in vitro pulldown assays. For the gel filtration analyses, 4 μM of purified ArhGAP12 derivatives or recombinant GST-ArhGAP1 (Cytoskeleton, GAS01) were incubated with 5 or 2 µM LatBactin, respectively, and loaded on a calibrated Superdex 200 (10:300) column (GE Healthcare) in 50 mM Tris, pH 6.8 and 7.6 respectively, 150 mM NaCl, 10 mM MgCl 2 and 1 mM DTT. The collected fractions were concentrated and a tenth of each fraction was analysed by SDS-PAGE and Coomassie brilliant blue staining. For the GST-pulldown experiments, glutathione-sepharose beads (GE Healthcare) were saturated with GST-ArhGAP12 or GST-ArhGAP32 from E. coli lysates and used as an affinity resin in a binding reaction with 10 µM LatB-actin in binding buffer (50 mM Tris, pH 7.0 and 8.5, respectively, 50 mM NaCl, and 5 mM MgCl 2 ) for 1 h at 4 °C. The resin was then washed four times in binding buffer and subjected to SDS-PAGE, Coomassie staining or western blotting. Coomassie brilliant blue staining was performed according to standard techniques and quantified using Image Studio after scanning with an Odyssey infrared scanner (Licor). Actin recovery was quantified relative to input GST-ArhGAP12. The unprocessed scans of the blots and Coomassie gels are shown in Supplementary Fig. 8 .
Crystallization, data collection and refinement of the ArhGAP12/G-actin complex. The protein complex was prepared by mixing purified ArhGAP12 ΔNΔP and LatB-actin at a molar ratio of 1:2 and further purified by Superdex 200 size-exclusion chromatography equilibrated in 20 mM Tris, pH 8, 50 mM NaCl, 3 mM MgCl 2 , 0.2 mM EGTA, 0.2 mM ATP and 0.3 mM TCEP. To grow crystals, the protein solution was concentrated to 30 mg ml −1
. The complex was crystallized at 20 °C using the sitting-drop vapour diffusion method. Drops of 0.5 μl consisted of a 1:1 (vol:vol) mixture of protein and a well solution containing 0.1 M bisTris propane, pH 6.5, 20% PEG 3350 and 0.2 M sodium thiocyanate. Crystals appeared after 5 d and reached their maximum size after 10 d. The crystals were cryoprotected in mother liquor supplemented with 20% glycerol and then flashfrozen in liquid nitrogen. X-ray data were collected at 100 K at the ID24 beamline (mx8015) of the Diamond Light Source synchrotron (DLS). Data collection and refinement statistics are summarized in Table 1 . The dataset was indexed, scaled and merged using xia2 (ref. 54 ). Molecular replacement was achieved using the high-resolution atomic coordinates of G-actin extracted from the RPEL2/LatBactin 13 structure (PDB ID 2V52) and the GAP domain extracted from ArhGAP15 structure (PDB ID 3BYI) in PHASER 55 . Refinement was carried out using Phenix 56 . Model building was conducted in COOT 57 . Model validation used PROCHECK 58 and the figures were prepared using the graphics program PYMOL 2.1.1 (ref.
59
). The asymmetric unit contains four copies of the complex. The ArhGAP12/G-actin structure has been deposited in PDB (ID 6GVC).
Protein affinity measurements. Fluorescence anisotropy assays were performed as described previously 34 . Dissociation constants were derived by nonlinear regression analysis of the data using Prism (GraphPad software). Biolayer interferometry analysis of G-actin binding to immobilized GST-ArhGAP12 was performed using the Octet Red96 (ForteBio); typical immobilization levels were higher than 2.5 nm. GST-ArhGAP12-loaded anti-GST biosensors were incubated with various concentrations of G-actin in the kinetics buffer (25 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20, 5 mM MgCl 2 , 0.5 mM TCEP and 1 mg ml −1 BSA). Binding experiments were performed in solid-black 96-well plates at 25 °C with an agitation speed of 1,000 r.p.m. Data analysis was done using the Octet software version 7.1 (ForteBio). Global fitting of the binding curves generated a best fit with a 1:1 model, and the kinetic association and dissociation constants were calculated. The quality of the fit was assessed by evaluation of the χ 2 and R 2 values generated from all the fitting analyses. The experiments were repeated at least three times.
Rho GTPase activity assays. GAP activity was measured using a colorimetric rhoGAP assay kit (Cytoskeleton, BK105). The reactions were performed in 20 µl with 4.75 µM rho GTPase and 2 µM ArhGAP12 derivatives (Supplementary Fig.  3b) in the presence or absence of 10 µM LatB-actin at 37 °C for the indicated time after the addition of 200 µM GTP. The release of inorganic phosphate (Pi) was detected at 650 nm using a SpectraMax Plus 384-well plate reader. A KH 2 PO 4 solution was used to calibrate the quantity of Pi (nmol) released to the absorbance. A nonlinear regression analysis was applied to the data using Prism (GraphPad software).
Cell lines. B16F0, B16F2, B16F10 melanoma cells, SV40 immortalized MEFs, NIH3T3 fibroblasts, MDCK II epithelial cells and MDA-MB-231 breast carcinoma cells were maintained in DMEM media with 10% fetal calf serum (FCS). Where indicated, the cells were serum starved (0.3% FCS) overnight, then treated for 30 min with 15% FCS, 100 ng ml −1 HGF (Millipore, GF414), 5 µM cytochalasin D (Merck, cat. no. 250255) or 1 µM LatB (Merck, cat. no. 428020). NIH 3T3 monoclonal lines stably expressing FLAG-tagged ArhGAP12 derivatives and the Tet repressor were generated using the pcDNA4TO-FLAG-ArhGAP12 and pcDNA6/TR (Invitrogen) plasmids, and selected for zeocin (200 µg ml ) resistance. Expression was induced overnight with 2 µg ml −1 tetracycline. B16F10 polyclonal lines conditionally expressing FLAGArhGAP12 derivatives were generated by lentiviral transduction using pTripz-FLAG-ArhGAP12 plasmids and selected for puromycin (0.5 µg ml −1 ) resistance. Expression was induced for 24 h with 2 µg ml −1 doxycycline. Cell growth was analysed following seeding and siRNA transfection of 50,000 cells in a well of a 6-well plate. Each day, cells of replicate wells were trypsinised, resuspended in media and counted using the Countess II instrument (Invitrogen). For the cellcycle analyses, cells were fixed after 2.5 h of BrdU incorporation, counterstained with propidium iodide and analysed by flow cytometry using standard methods and FlowJo software as previously described 47 . All cell lines tested negative for mycoplasma and were authenticated by short-tandem-repeat profiling by Crick Cell Services.
Transfection, immunoblotting and immunofluorescence. Cells were transfected with expression plasmids using Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen, cat. no. 11668-019). Cells were reverse transfected with RNAi oligonucleotides using Lipofectamine RNAiMax (Invitrogen, cat. no. 13778-150). The siRNAs used were: control, UUCUCCGAACGUGUCACGU; MRTF-A/B, UGGAGCUGGUGGAGAAGAA; ArhGAP32, L057176-01; Rac1, L041170-00; Cdc42, L043087-01; ArhGAP12, mouse L-040581-01 (a pool of oligonucleotides J-040581-9, -10, -11 and -12) and human L-008729-01 Dharmacon smartpools. In experiments where siRNA-resistant ArhGAP12 derivatives were re-expressed, either transiently or in ArhGAP12-expressing lines, the ArhGAP12 siRNA oligonucleotide 11 (GCAUUGAGCAUGUCGAAGA) was used. The oligonucleotide used to target ArhGAP12 in MDCK II cells was GAACAGAACUGCUAAUUCAUU. The assays were performed 72 h after siRNA transfection, with the exception of the experimental metastasis assay (40 h); where required, siRNA-depleted cells were transfected with ArhGAP12 plasmids 24 h before analysis.
Whole-cell extract preparation and immunoblotting were performed using standard techniques. The unprocessed scans of blots are shown in Supplementary  Fig. 8 . For the phenotypic experiments, samples were taken for analysis of protein expression at the time that the assays were commenced. The antibodies used were against β-actin (Santa-Cruz Biotechnology, clone C4, sc47778; 1:1,000 dilution), haemagglutinin (HA; Roche, 3F10, 11867431001; 1:1,000 dilution), Rac (Millipore, clone 23A8, 05-389; 1:500 dilution), Cdc42 (Millipore, 05-542; 1:250 dilution), MRTF-A (Santa-Cruz Biotechnology, C-19, sc21558; 1:1,000 dilution), MRTF-B (Bethyl Laboratories, A302-768; 1:1,000 dilution), Myc (Crick Biological Research Facilities, clone 9E10; 1:1,000 dilution), ArhGAP12 (Sigma, HPA000412; 1:1,000 dilution), α-tubulin (Sigma, clone B5-1-2, T5168; 1:6,000 dilution), GST (Sigma, G7781; 1:10,000 dilution) and FLAG (Sigma, F7425; 1:1,000 dilution). Secondary antibodies were IRDye-680LT or -800CW conjugated (Licor, cat. nos 925-68022, -68023, -32212, -32214 and -32219; 1:10,000 dilution). Alexa Fluor 790-conjugated light-chain-specific IgG (Jackson Immunoresearch laboratories, cat. nos. 211-652-171 and 115-655-174; 1:5,000 dilution) were used for the coimmunoprecipitation experiments in MDCK cells. Immunoblots were scanned with an Odyssey infrared scanner (Licor) and quantified using Image Studio. The immunofluorescence assays were carried out as described previously 11 . F-actin was detected with Alexa Fluor 647 or Texas Red Phalloidin (Invitrogen, A22287 and T7471) and DNA was counterstained using DAPI. F-actin staining was imaged in 96-well glass-bottom plates on the automated Cellomics Arrayscan VTi and the intensity was measured using the Target Activation Bioapplication (Cellomics). Where indicated, cells were imaged using a confocal Laser Scanning Microscope LSM710 controlled by the Zen software (Zeiss), with a ×63/1.40 oil Plan Apochromat objective lens (Zeiss), utilizing the 405 (DAPI), 488 (GFP) and 561 nm (Texas Red) lasers for excitation, and a pinhole set at 1 Airy unit.
Immunoprecipitation and Rac/Cdc42-pulldown experiments. Cells were lysed in IP buffer (50 mM Tris, pH 7.8, 100 mM NaCl, 1% Triton X-100, 1 mM DTT and protease inhibitors (Roche)) for FLAG immunoprecipitation. The soluble fraction was pre-cleared with Protein A-Sepharose beads (Sigma) and incubated with M2-Agarose beads (2 h, 4 °C; Sigma) with rotation. ArhGAP12 immunoprecipitation was performed with essentially the same protocol with the exception that it used 50 mM NaCl, Dynabeads Protein G (Invitrogen) and a pan-ArhGAP12 polyclonal antibody generated by Crick Biological Research Facilities. The beads were washed four times in IP buffer and resuspended in SDS Laemmli buffer. Actin recovery was quantified relative to the input. The Rac/Cdc42-pulldown experiments were performed using 15 µl GST-tagged human PAK1 p21-binding domain (residues 67-150; 1 µg µl −1 ) bound to glutathione magnetic beads (Millipore, cat. no. 17-10394), carried out according to the manufacturer's instructions. Rac/Cdc42 GTP loading was quantified relative to total Rac/Cdc42. ArhGAP12 recovery was quantified relative to the input.
Gene expression. Total RNA was isolated and cDNA was synthesized as described previously 16 . Quantities of cDNA corresponding to 10 ng RNA were analysed by a SYBR Green-based real-time quantitative PCR (Invitrogen) using the ABI Prism 7900HT and QuantStudio 5 detection systems (Applied Biosystems). Absolute quantification of cDNA abundance was determined using a mouse genomic-DNA standard. Data were normalized to the abundance of Gapdh cDNA. Gene-specific exonic primers were as follows: Arhgap9, CAGAGGGCACTGACCAGAAGA and TTGGCGATTAGCCGCTTTAA; Arhgap12, ACAACCCAGGAGCGAACCT and TCGGCTTGTGCTCACATCTC; Arhgap15, CTACAGGAGCTGTGCAAATGAGA and TTGGCTCTGCCTGTCTTGGT; Arhgap27, GAGGCCTGGAAAGCGACTT and GGGTCGTCTCTGTAGGAATTTACG; Arhgap32, CACCGCCTCCGAAAAATG and TGCAGACTCAGCTAACGCTAGTG; Arhgap33, TGGCGATGATCTGGATTTCA and AAGTCAAGTCCCCGAAGTCCTT; Srf, GGTTGGAGGGAACCACTGT and CTGGGAGAAGGGGGAAGAC; Cyr61, AATCGCAATTGGAAAAGGCA and TGAAAAGAACTCGCGGTTCG; Vcl, AGCCCAGATGCTTCAGTCAGA and GGTCAGATGTGCCAGAAAGGA; and Gapdh, TCTTGTGCAGTGCCAGCCT and CAATACGGCCAAATCCGTTCA.
The intronic primers were as follows: Cyr61, CGTAAACTGCCCTGAGCCTA and GACGCGATCGAGACACTTCT; Klf7, CACTGGCTCCCTATACCGTG and GATCCAAAGCAGGGTTTGCC; Slc2a1, CCGGATTTACGGAACCCCTC and GCAAAGGCGGGACAAGAAAG; Srf, TCAAGGCAGCAGCAGTTTCT and CAGGCAGGGTTAGGAACCAG; Vcl, CGTCACTTGCGTTGAGTACC and GAAACCACCCACAGGTTGGA; and Zyx, CAACCTGGCTCGTTCTCACT and GACCATAACGAGGGGCTCAG.
Time-lapse FRET imaging. Cells were transiently transfected with the RaichuEVRac FRET biosensor 45 24 h before imaging. Cells were imaged in phenol red-free DMEM using an inverted microscope with the Perfect Focus System (Nikon Ti2) controlled by the Micro-Manager software 60 , and a ×60/1.4 NA Plan Apochromat objective lens (Nikon), an ASI XY stage with piezo Z, a scientific CMOS camera (Photometrics Prime), a SpectraX LED light engine (Lumencor) utilizing the blue excitation light fitted with a 440/20 nm filter, an FF459/526/596-Di01 dichroic mirror (Semrock) and two emission filters (FF01-482/25 for cyan fluorescent protein (CFP) and FF01-544/24 for yellow fluorescent protein). After background subtraction, FRET/CFP ratio images were generated using Metamorph (Molecular Devices) and represented in the intensity-modulated display mode (eight colours). The CFP and FRET intensities were averaged over the whole cell area using Fiji software 61 . For the kinetics experiments, data were expressed relative to the start of the experiment and normalized as indicated. The determination of t 50 (time to downregulate to 50% of the maximum activity) for each condition was calculated using the formula: t 50 = t(Min + 50% (Max − Min)) − t(Max) where t represents time, Min the minimum value and Max the maximum value ( Supplementary Figs. 4d,6b) .
Invadopodia assay. Invadopodia assays were carried out in 96-well glassbottom plates coated with poly-d-lysine (50 µg ml −1 ), functionalised with 0.5% glutaraldehyde, and coated for 30 min at 37 °C with 33 µg ml −1 Oregon Green Gelatin (Invitrogen, G13186) and 1% unlabelled gelatin in PBS. Cells (3,000 per well) were seeded and incubated for 16 h, fixed with 4% paraformaldehyde and stained for F-actin and DNA. Images were captured on the Cellomics Arrayscan VTi with a ×5 objective and analysed using the automated Morphology Explorer Bioapplication (Cellomics). Quantitation was by loss of fluorescence normalized to cell number.
Animals and experimental metastasis assay. The experimental metastasis assays were performed as described previously 47 . B16F0 (900,000 cells) and B16F10 cells (200,000 or 500,000 cells) were injected into the tail vein of seven-weekold C57BL/6J female mice, and their lungs were analysed 12 d after injection by counting the surface metastatic foci macroscopically. For the phenotypic rescue experiments, the mice were given water supplemented with 2 mg ml −1 doxycycline and 1% sucrose 2 d before injection, and for the duration of the experiment, which was replaced every 2 d. ArhGAP12-knockout embryos were obtained from Jackson Laboratories and knockout MEFs were generated and genotyped using standard techniques. Animal experimentation complied with all ethical regulations and was carried out under the UK Home Office Project licence P7C307997 in the Crick Biological Research Facilities.
Multiple sequence alignment and phylogenetic tree. The protein sequences of all mouse rhoGAP domains and 50 N-terminal amino acids were obtained from the RefSeq database. A multiple sequence alignment was generated using default parameters in Clustal Omega and used to produce a phylogenetic tree by the neighbour-joining method. The alignment was edited and Clustal X-coloured in Jalview (blue, hydrophobic; red, positively charged; magenta, negatively charged; green, polar; pink, cysteine; orange, glycine; yellow, proline; cyan, aromatic; and white, unconserved). The cladogram was drawn using Dendroscope.
Statistics and reproducibility. Each experiment was performed at least three times. Unless indicated otherwise, non-parametric two-tailed Mann-Whitney tests were used to determine statistical significance, where *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant. Error bars represent the s.e.m. for n independent experiments, as indicated in the legends. Statistical analyses were performed using Prism (GraphPad software). The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. All studies must disclose on these points even when the disclosure is negative.
Sample size
The number of independent experiments (n) performed for each assay is indicated in the figures. Each experiment was performed at least three times. No sample size calculation was done for this study. Appropriate sample size required for statistical power was estimated empirically. Statistical significance was determined as indicated in the figure legends. Unless indicated otherwise, nonparametric two-tailed Mann-Whitney tests were used to determine statistical significance. Statistical analyses were performed using Prism (GraphPad software).
Data exclusions In the kinetics experiments using time-lapse FRET imaging with the RaichuEV-Rac probe, only cells responding to the HGF treatment (increased FRET) were analysed. A high percentage of cells responded (around 90%). This criterion was decided before performing the experiments.
Replication
Experiments were successfully repeated independently at least three times, as indicated in the figures (n experiments). Moreover, in vivo data were confirmed in various cell lines (NIH 3T3, B16F0, B16F2, B16F10, MDA-MB-231), and in different conditions (serum-starved, growing, serum-stimulated). In vitro data were further confirmed using different derivatives of the proteins.
Randomization Animals were randomly allocated into experimental groups. All experiments were randomized.
Blinding
The data collection and analyses were done blindly when the experiments allowed. Whenever possible, automated analyses (F-actin and invadopodia assays) were performed.
Reporting for specific materials, systems and methods 
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
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The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
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Methodology Sample preparation
For cell cycle analysis, established cell lines were treated with 10 μM BrdU for 2.5h, trypsinised, fixed in 70% cold ethanol and washed twice in PBS. Following anti-BrdU staining, cells were incubated for 30 minutes at room temperature in PI buffer (50 ug/ ml propidium iodide (PI); Sigma) containing 25 mg/ml RNaseA.
Instrument
LSR Fortessa A (BD Biosciences) was used.
Software FACS Diva (BD Biosciences) was used for data collection, and FlowJo 9.9 for data analysis.
